MAYO CLINIC LABORATORIES

1-800-533-1710

TLPFD

T-Cell Lymphoma Panel, Diagnostic, FISH, Varies

Patient ID	Patient Name		Birth Date	Sex	Age
C7028846-0006403	TESTING, TLPFD-ABNORMAL		1991-05-15	M	33
Order Number	**Client Order Number**	**Ordering Physician**	**Report Notes**		
X100498316	X100498316	unknown			
Account Information		**Collected**			
C7028846 DLMP Rochester		07 May 2025 08:35			

T-lymphoma BM/BL panel, Diag, FISH

Result Summary

MCR

Abnormal

Interpretation

MCR

The result is abnormal and indicates 80% of nuclei have a rearrangement of the TRA gene region. No TCL1A rearrangement was identified. While also identified in other T-cell lymphoproliferative disorders, a rearrangement of the TRA gene region is observed in essentially all cases of T-Prolymphocytic leukemia/T-PLL. In the absence of a TCL1A rearrangement, approximately 5–10% of T-PLL cases harbor a t(X;14) involving the TRA (at 14q11.2) and MTCP1 (at Xq28) gene regions.

Clinical and pathologic correlation is recommended.

For monitoring response to therapy, FISH for TRA is available, test TLPMF [T-cell Lymphoma B/BM, Spec FISH].

Reference:
Leukemia. 36(7):1720–1748, 2022. PMCID: PMC9214472

Result Table

MCR

Abnormality Name	Result	Abn%	Cutoff%
+7q31(D7Z1x2,D7S486x3)	Normal		<10.0
+8(D8Z2,MYC)x3	Normal		<7.0
14q11.2(TRA sep)	Abnormal	80	<15.0
14q32(TCL1A sep)	Normal		<15.0

Result

MCR

nuc ish (TRA)x2(5'TRA sep 3'TRA)x1[80/100]

Reason for Referral

MCR

r/o T-cell lymphoma

Specimen

MCR

Bone Marrow

Source

MCR

Left iliac crest

Method

MCR

Locus and probes	[Strategy;#Nuclei;Vendor]
7CEN(D7Z1), 7q31(D7S486)	[COPY#;100;AM]
8CEN(D8Z2), 8q24.21(MYC)	[COPY#;100;AM]
14q11.2(5'TRA,3'TRA)	[BAP;100;LDT]
14q32.1(5'TCL1A,3'TCL1A)	[BAP;100;LDT]

Probe strategies include:
BAP=break-apart probe;
COPY#=region gain and loss.
Scoring Method: Manual

Probe vendors include:
LDT = Mayo Clinic Developed
AM = Abbott Molecular, Inc (Des Plaines, IL)

Updated Gene Symbols
TRA: previously reported as TRAD

Disclaimer

MCR

Applicable to Analyte Specific Reagent (ASR) and Laboratory Developed Tests (LDT). This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the U.S. Food and Drug Administration. This FISH test does not rule out other chromosome abnormalities.

Released By

MCR

Xinjie Xu, Ph.D.

Received: 13 May 2025 11:04 **Reported:** 21 May 2025 14:23

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	Nikola Baumann Ph.D.	24D0404292